Loading clinical trials...
Loading clinical trials...
An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma
Conditions
Interventions
Abemaciclib
LY3023414
+2 more
Locations
32
United States
Yale University School of Medicine
New Haven, Connecticut, United States
Illinois CancerCare
Peoria, Illinois, United States
Research Medical Center
Kansas City, Missouri, United States
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Sarah Cannon Cancer Center
Nashville, Tennessee, United States
Start Date
January 12, 2017
Primary Completion Date
April 20, 2018
Completion Date
November 9, 2018
Last Updated
November 20, 2019
NCT02600949
NCT06921928
NCT06423326
NCT07542041
NCT06821997
NCT07076121
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions